Switch theme
Sign up to access all valuation multiples
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
1999
180
LTM Revenue $123M
LTM EBITDA $66.4M
$198M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Genfit has a last 12-month revenue (LTM) of $123M and a last 12-month EBITDA of $66.4M.
In the most recent fiscal year, Genfit achieved revenue of $75.3M and an EBITDA of $9.3M.
Genfit expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genfit valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $123M | XXX | $75.3M | XXX | XXX | XXX |
| Gross Profit | $123M | XXX | $74.9M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | $66.4M | XXX | $9.3M | XXX | XXX | XXX |
| EBITDA Margin | 54% | XXX | 12% | XXX | XXX | XXX |
| EBIT | $38.7M | XXX | $3.6M | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $32.7M | XXX | $1.7M | XXX | XXX | XXX |
| Net Margin | 27% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Genfit's stock price is EUR 4 (or $4).
Genfit has current market cap of EUR 196M (or $220M), and EV of EUR 176M (or $198M).
See Genfit trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $198M | $220M | XXX | XXX | XXX | XXX | $0.49 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Genfit has market cap of $220M and EV of $198M.
Genfit's trades at 2.6x EV/Revenue multiple, and 21.2x EV/EBITDA.
Equity research analysts estimate Genfit's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genfit has a P/E ratio of 6.7x.
See valuation multiples for Genfit and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $220M | XXX | $220M | XXX | XXX | XXX |
| EV (current) | $198M | XXX | $198M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 3.0x | XXX | 21.2x | XXX | XXX | XXX |
| EV/EBIT | 5.1x | XXX | 54.5x | XXX | XXX | XXX |
| EV/Gross Profit | 1.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 6.7x | XXX | 129.8x | XXX | XXX | XXX |
| EV/FCF | 11.2x | XXX | 12.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGenfit's last 12 month revenue growth is 10%
Genfit's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Genfit's rule of 40 is -67% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genfit's rule of X is 80% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Genfit and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | -6% | XXX | XXX | XXX |
| EBITDA Margin | 54% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -67% | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 80% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 71% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 95% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genfit acquired XXX companies to date.
Last acquisition by Genfit was XXXXXXXX, XXXXX XXXXX XXXXXX . Genfit acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Genfit founded? | Genfit was founded in 1999. |
| Where is Genfit headquartered? | Genfit is headquartered in France. |
| How many employees does Genfit have? | As of today, Genfit has 180 employees. |
| Who is the CEO of Genfit? | Genfit's CEO is Mr. Pascal Prigent. |
| Is Genfit publicy listed? | Yes, Genfit is a public company listed on PAR. |
| What is the stock symbol of Genfit? | Genfit trades under GNFT ticker. |
| When did Genfit go public? | Genfit went public in 2006. |
| Who are competitors of Genfit? | Similar companies to Genfit include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Genfit? | Genfit's current market cap is $220M |
| What is the current revenue of Genfit? | Genfit's last 12 months revenue is $123M. |
| What is the current revenue growth of Genfit? | Genfit revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Genfit? | Current revenue multiple of Genfit is 1.6x. |
| Is Genfit profitable? | Yes, Genfit is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Genfit? | Genfit's last 12 months EBITDA is $66.4M. |
| What is Genfit's EBITDA margin? | Genfit's last 12 months EBITDA margin is 54%. |
| What is the current EV/EBITDA multiple of Genfit? | Current EBITDA multiple of Genfit is 3.0x. |
| What is the current FCF of Genfit? | Genfit's last 12 months FCF is $17.6M. |
| What is Genfit's FCF margin? | Genfit's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Genfit? | Current FCF multiple of Genfit is 11.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
